

Notice: This document has been translated from a part of the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

## Summary of Consolidated Financial Results (For the Second Quarter ended September 30, 2023) [Under Japanese GAAP]

November 8, 2023  
Tokyo Stock Exchange

Company name: KYORIN Pharmaceutical Co., Ltd.

Code number: 4569

Web site: <https://www.kyorin-pharm.co.jp/>

Representative : Yutaka Ogihara, Representative Director, President and Chief Executive Officer

Contact: Sakurou Banba, Director, Finance & Accounting

TEL (03) 3525-4701

Scheduled date for submitting quarterly report: November 14, 2023

Scheduled date for starting dividend payment: December 4, 2023

Supplementary Materials Prepared for the Quarterly Financial Statements: Yes

Presentation Held to Explain the Quarterly Financial Statements: Yes (for institutional investor, securities analysts)

(Amounts rounded down to the nearest million yen)

### 1. Consolidated Results for Six Months Ended September 30, 2023 (From April 1, 2023, to September 30, 2023)

#### (1) Consolidated Operating Results

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Million yen	%	Million yen	%	Million yen	%	Million yen	%
Six months ended September 30, 2023	54,937	11.9	1,144	47.2	1,387	18.4	1,757	41.4
September 30, 2022	49,093	-0.0	777	—	1,171	309.8	1,242	921.1

(Note) Comprehensive income: For six months ended September 30, 2023: 2,309 million yen (10.8%),  
For six months ended September 30, 2022: 2,084 million yen (— %)

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended September 30, 2023	30.66	—
September 30, 2022	21.69	—

#### (2) Consolidated Financial Position

	Total assets	Net assets	Equity ratio
	Million yen	Million yen	%
As of September 30, 2023	176,175	126,226	71.6
March 31, 2023	176,045	125,461	71.3

(Note) Equity: As of September 30, 2023: 126,226 million yen, As of March 31, 2023: 125,461 million yen

### 2. Dividends

(Record date)	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2023	—	20.00	—	32.00	52.00
Fiscal year ending March 31, 2024	—	20.00			
Fiscal year ending March 31, 2024 (Forecast)			—	32.00	52.00

(Note) Whether the most recent dividend forecast has been revised: No

### 3. Forecast of Consolidated for the Year Ending March 31, 2024 (From April 1, 2023, to March 31, 2024)

(Percentage changes relative to previous corresponding period)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Earnings per share
	Million yen	%	Million yen	%	Million yen	%	Million yen	%	Yen
Full year	116,200	2.6	6,000	17.1	6,500	11.5	4,900	3.7	85.51

(Note) Whether the most recent earning forecast have been revised: No

4. Other

(1) Changes in major subsidiaries during the period

(Change of specified subsidiaries associated with a change of the scope of consolidation): Yes

Newly included: None

Excluded: 1 company (The former Kyorin Pharmaceutical Co. Ltd.)

(2) Application of special accounting methods in the preparation of quarterly financial statements : Yes

(3) Changes in accounting policies, changes in accounting estimates and restatements

(i) Changes due to mandatory changes of accounting standards : None

(ii) Changes other than i) : None

(iii) Changes in accounting estimates : Yes

(iv) Restatements : None

(4) Number of shares issued (common stock)

(i) Number of shares issued and outstanding at the end of the fiscal year (including treasury stock)

As of September 30, 2023: 64,607,936 shares,

Fiscal year ended March 31 2023: 64,607,936 shares

(ii) Number of shares of treasury stock at the end of the fiscal year

As of September 30, 2023: 7,159,060 shares,

Fiscal year ended March 31 2023: 7,304,066 shares

(iii) Averaged number of shares of during the period

As of September 30, 2023: 57,329,937 shares,

As of September 30, 2022: 57,302,263 shares

\* This quarterly financial report is not subject to audit procedures by Certified Public Accountants or audit firm.

\* Explanations about the appropriate use of the business forecasts and other noteworthy points.

These forecast performance figures are based on information currently available to the Company and may include uncertain factors or risk that affect our future performance. Accordingly, actual business results may materially differ from the forecasted figures due to various factors in the future.

(Methods for obtaining supplementary materials and content of financial results disclosure)

Supplementary materials will be made available on the Company's website in conjunction with the Summary of Consolidated Financial Results.